ClinicalTrials.gg
CompletedNCT03073213Updated Jul 22, 2020Results posted

A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris

A Phase 1 interventional study of Ixekizumab in Psoriasis, sponsored by Eli Lilly and Company. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
18th of 22
32 · median 156
Started
2017
with 1 other
Phase 1
2 of 22
none open now
Registered
13th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 18th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 1, and was the 13th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of the study is to research how much ixekizumab enters the bloodstream and how long the body takes to get rid of the drug and the safety of ixekizumab and any side effects that might be associated with it. The study has two parts: A single-dose part and multiple-dose part. The single dose part of this study will last up to 24 weeks, including the screening period. The multiple dose part of this study will last up to 32 weeks including the screening period.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged ≥18 years.
  • Diagnosis of chronic plaque psoriasis for ≥6 months before baseline.
  • Candidates for phototherapy and/or systemic therapy.
  • ≥10% body surface area (BSA) involvement at screening and baseline.
  • static Physician's Global Assessment (sPGA) score ≥3, and Psoriasis Area and Severity Index (PASI) score ≥12 at screening and baseline.

Exclusion criteria

Exclusion Criteria:

  • flare of psoriasis during the 12 weeks before baseline.
  • Systemic nonbiologic psoriasis therapy or phototherapy within 4 weeks. prior to baseline or topical psoriasis treatment or medicated shampoo within 2 weeks prior to baseline .
  • Current or recent use of any biologic agent within the required .
  • Clinical evidence or suspicion of active tuberculosis or previously had evidence of active tuberculosis and did not receive appropriate and documented treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Ixekizumab single dose

    Participants received single dose of 80mg Ixekizumab by subcutaneous injection.

    Drug: Ixekizumab

  • Experimental
    Ixekizumab Multiple Regimen 1 (80mg Q2W)

    Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.

    Drug: Ixekizumab

  • Experimental
    Ixekizumab Multiple Regimen 2 (80mg Q4W)

    Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.

    Drug: Ixekizumab

Interventions

  • Administered as subcutaneous (SC) injection

    Also known as: LY2439821

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Single Dose)

    Pharmacokinetics (PK): Cmax is the maximum observed concentration of Ixekizumab into serum.

    Time frame: Single dose: Predose, day 1, 3, 5, 8, 11, 15, 22, 29, 43, 57, 85, 113, 141

  2. Pharmacokinetics: Area Under Concentration From Time Zero to Infinity (AUC 0toinf) of Ixekizumab (Single Dose)

    Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) from time zero to infinity was reported.

    Time frame: Predose, day 1, 3, 5, 8, 11, 15, 22, 29, 43, 57, 85, 113, 141

  3. Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Multiple Dose)

    Pharmacokinetics: Cmax is the maximum observed concentration of Ixekizumab into serum.

    Time frame: day 57 (pre-dose), 59, 61, 64, 67, 71, 78, 85, 99, 113, 141, 169, 197

  4. Pharmacokinetics: Area Under Concentration From Time Zero to 336h (AUC 0 to 336h) of Ixekizumab (Multiple Dose)

    Pharmacokinetics: Area under concentration of Ixekizumab from time Zero to 336h (AUC 0 to 336h) was reported (Multiple dose).

    Time frame: day 57 (Pre-dose), 59, 61, 64, 67, 71

  5. Pharmacokinetics: Area Under Concentration From Time Zero to 672h (AUC 0 to 672h) of Ixekizumab (Multiple Dose)

    Pharmacokinetics: Area under concentration of Ixekizumab from time zero to 672h (AUC 0 to 672h) was reported (Multiple dose).

    Time frame: day 57 (Pre-dose), 59, 61, 64, 67, 71, 78, 85

07

Results

Posted Jul 22, 2020

Participant flow

All the re-enrolled participants from single dose period (SDP) to multiple dose period (MDP) have been washed out and screened for eligibility to MDP.

Single Dose Period
Participant flow — Single Dose Period
MilestoneIxekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple Dose
Started1200
Completed1200
Not completed000
Multiple Dose Period
Participant flow — Multiple Dose Period
MilestoneIxekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple Dose
Started01415
Participants enrolled from single dose072
Completed01414
Not completed001
Withdrew: Protocol violation001

Outcome measures

PrimaryPharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Single Dose)

Pharmacokinetics (PK): Cmax is the maximum observed concentration of Ixekizumab into serum.

Time frame:
Single dose: Predose, day 1, 3, 5, 8, 11, 15, 22, 29, 43, 57, 85, 113, 141
Reported as:
Geometric mean · Microgram per milliliter (ug/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Single Dose)
Microgram per milliliter (ug/mL)Ixekizumab Single Dose
Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Single Dose)6.90 ± 43
PrimaryPharmacokinetics: Area Under Concentration From Time Zero to Infinity (AUC 0toinf) of Ixekizumab (Single Dose)

Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) from time zero to infinity was reported.

Time frame:
Predose, day 1, 3, 5, 8, 11, 15, 22, 29, 43, 57, 85, 113, 141
Reported as:
Geometric mean · Microgram*day per milliliter (ug*day/mL)
Pharmacokinetics: Area Under Concentration From Time Zero to Infinity (AUC 0toinf) of Ixekizumab (Single Dose)
Microgram*day per milliliter (ug*day/mL)Ixekizumab Single Dose
Pharmacokinetics: Area Under Concentration From Time Zero to Infinity (AUC 0toinf) of Ixekizumab (Single Dose)147 ± 48
PrimaryPharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Multiple Dose)

Pharmacokinetics: Cmax is the maximum observed concentration of Ixekizumab into serum.

Time frame:
day 57 (pre-dose), 59, 61, 64, 67, 71, 78, 85, 99, 113, 141, 169, 197
Reported as:
Geometric mean · Microgram per milliliter (ug/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Multiple Dose)
Microgram per milliliter (ug/mL)Ixekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple Dose
Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Multiple Dose)19.9 ± 2713.4 ± 32
PrimaryPharmacokinetics: Area Under Concentration From Time Zero to 336h (AUC 0 to 336h) of Ixekizumab (Multiple Dose)

Pharmacokinetics: Area under concentration of Ixekizumab from time Zero to 336h (AUC 0 to 336h) was reported (Multiple dose).

Time frame:
day 57 (Pre-dose), 59, 61, 64, 67, 71
Reported as:
Geometric mean · Microgram*day per milliliter (ug*day/mL)
Pharmacokinetics: Area Under Concentration From Time Zero to 336h (AUC 0 to 336h) of Ixekizumab (Multiple Dose)
Microgram*day per milliliter (ug*day/mL)Ixekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple Dose
Pharmacokinetics: Area Under Concentration From Time Zero to 336h (AUC 0 to 336h) of Ixekizumab (Multiple Dose)224 ± 25136 ± 31
PrimaryPharmacokinetics: Area Under Concentration From Time Zero to 672h (AUC 0 to 672h) of Ixekizumab (Multiple Dose)

Pharmacokinetics: Area under concentration of Ixekizumab from time zero to 672h (AUC 0 to 672h) was reported (Multiple dose).

Time frame:
day 57 (Pre-dose), 59, 61, 64, 67, 71, 78, 85
Reported as:
Geometric mean · Microgram*day per milliliter (ug*day/mL)
Pharmacokinetics: Area Under Concentration From Time Zero to 672h (AUC 0 to 672h) of Ixekizumab (Multiple Dose)
Microgram*day per milliliter (ug*day/mL)Ixekizumab 80mg Q4W Multiple Dose
Pharmacokinetics: Area Under Concentration From Time Zero to 672h (AUC 0 to 672h) of Ixekizumab (Multiple Dose)213 ± 29

Adverse events

Collected over Baseline to end of the study (up to 20 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab Single Dose0/12 (0%)0/12 (0%)11/12 (91.7%)
Ixekizumab 80mg Q2W Multiple Dose0/14 (0%)1/14 (7.1%)11/14 (78.6%)
Ixekizumab 80mg Q4W Multiple Dose0/15 (0%)0/15 (0%)12/15 (80%)
Most frequent serious events
Most frequent serious events
EventIxekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple Dose
Bile duct stoneHepatobiliary disorders0/121/140/15
CholecystitisHepatobiliary disorders0/121/140/15
CholelithiasisHepatobiliary disorders0/121/140/15
Most frequent other events
Showing 10 of 84
Most frequent other events
EventIxekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple Dose
PruritusSkin and subcutaneous tissue disorders5/126/142/15
Upper respiratory tract infectionInfections and infestations2/125/143/15
Protein urine presentInvestigations4/122/140/15
FlatulenceGastrointestinal disorders3/120/140/15
DiarrhoeaGastrointestinal disorders0/123/142/15
Electrocardiogram abnormalInvestigations1/123/142/15
NasopharyngitisInfections and infestations2/121/141/15
DizzinessNervous system disorders2/121/140/15
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/120/142/15
UrticariaSkin and subcutaneous tissue disorders2/121/141/15

Baseline characteristics

All the re-enrolled participants from SDP to MDP have been washed out and screened for eligibility to MDP.

Age, Continuous
Age, Continuous(years)Ixekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple DoseTotal
Single Dose49.0 ± 12.1——49.0 ± 12.1
Multiple Dose—45.6 ± 12.545.5 ± 16.145.6 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)Ixekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple DoseTotal
Single Dose — Female2002
Single Dose — Male100010
Multiple Dose — Female0358
Multiple Dose — Male0111021
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ixekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple DoseTotal
Single Dose Phase — Hispanic or Latino0000
Single Dose Phase — Not Hispanic or Latino120012
Single Dose Phase — Unknown or Not Reported0000
Multiple Dose Phase — Hispanic or Latino0000
Multiple Dose Phase — Not Hispanic or Latino0141529
Multiple Dose Phase — Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ixekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple DoseTotal
Single Dose Phase — American Indian or Alaska Native0000
Single Dose Phase — Asian120012
Single Dose Phase — Native Hawaiian or Other Pacific Islander0000
Single Dose Phase — Black or African American0000
Single Dose Phase — White0000
Single Dose Phase — More than one race0000
Single Dose Phase — Unknown or Not Reported0000
Multiple Dose Phase — American Indian or Alaska Native0000
Multiple Dose Phase — Asian0141529
Multiple Dose Phase — Native Hawaiian or Other Pacific Islander0000
Multiple Dose Phase — Black or African American0000
Multiple Dose Phase — White0000
Multiple Dose Phase — More than one race0000
Multiple Dose Phase — Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Ixekizumab Single DoseIxekizumab 80mg Q2W Multiple DoseIxekizumab 80mg Q4W Multiple DoseTotal
China — Single Dose120012
China — Multiple Dose0141529
08

Study locations

3 sites
  • Xiangya Hospital, Central South University
    Changsha, Hunan, China
  • Second Affiliate Hospital of Zhejiang Medical University
    Hangzhou, Zhejiang 310009, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University
    Shanghai, 200025, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in May 2019, 25 months.

Results were first posted in Jul 2020, 1 year 2 months after primary completion.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 25 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2017
First posted
Mar 8, 2017
StartActual
Apr 13, 2017
Primary completionActual
May 14, 2019
CompletionActual
May 14, 2019
Results first posted
Jul 22, 2020
Last update
Jul 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03073213
Responsible party
Sponsor
First posted
Mar 8, 2017
Start date
Apr 13, 2017
Primary completion
May 14, 2019
Completion
May 14, 2019
Results posted
Jul 22, 2020
Last update
Jul 22, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion